Get Your Personalized Supplement StackSupplement Stack Quiz

Anabolic Gaining Agents

Also known as: Anabolic Gaining Agents, Anabolic steroids, Synthetic androgens, AAS, Testosterone esters, Nandrolone, Stanozolol, Anabolic-Androgenic Steroids

Overview

Anabolic-Androgenic Steroids (AAS) are synthetic compounds structurally similar to testosterone, designed to promote muscle growth (anabolism) and androgenic effects. They are categorized as performance-enhancing drugs or hormonal supplements. Clinically, AAS are prescribed for conditions such as muscle wasting, hypogonadism, and chronic diseases causing cachexia. Illicitly, they are misused by athletes and bodybuilders to enhance muscle mass and strength. While effective in promoting protein synthesis and increasing lean body mass, AAS carry significant health risks. Extensive research, including randomized controlled trials and meta-analyses, has focused on their efficacy and adverse effects, providing high-quality evidence, though many studies are short-term and may not reflect real-world abuse patterns.

Benefits

Anabolic-Androgenic Steroids (AAS) offer several benefits, primarily in muscle growth and strength. Research indicates a moderate increase in lean body mass (standardized mean difference [SMD] ~0.62) and a small absolute increase in muscle strength (SMD ~0.27) in healthy exercising adults compared to placebo. In chronic disease populations, such as those with COPD, AAS significantly increased body weight by approximately 1.38 kg and fat-free mass by about 1.56 kg over placebo. These benefits are more pronounced in clinical populations experiencing muscle wasting than in healthy athletes using low-to-moderate doses. The increase in muscle strength is approximately 52% greater than placebo, and lean mass gains are clinically relevant in wasting conditions. Some evidence also suggests improved hemoglobin levels and free testosterone in clinical populations. Most studies are short-term, limiting data on long-term effects and sustainability.

How it works

Anabolic-Androgenic Steroids (AAS) exert their effects primarily by binding to androgen receptors located in muscle cells. This binding activates the mTOR signaling pathway, which is crucial for enhancing protein synthesis and promoting muscle hypertrophy (growth). While primarily affecting skeletal muscle, AAS also influence lipid metabolism, the cardiovascular system, the endocrine system, and the central nervous system. Their molecular targets include the androgen receptor and hepatic lipase, which impacts lipid profiles. The absorption and bioavailability of AAS vary depending on their formulation; oral forms are often chemically modified to resist hepatic metabolism, while injectable forms bypass first-pass metabolism, leading to higher bioavailability and longer half-lives.

Side effects

The use of Anabolic-Androgenic Steroids (AAS) is associated with significant adverse effects, particularly at supraphysiological doses or with prolonged use. Common side effects, affecting more than 5% of users, include acne, irritability, mood swings, headaches, and muscle cramps. Less common side effects (1-5%) involve altered lipid profiles (reduced HDL, increased LDL), hypertension, gynecomastia (breast enlargement in males), and testicular atrophy. Rare but severe side effects (less than 1%) can include early dementia, sudden cardiac death, and various neuropsychiatric disorders. AAS can interact with cardiovascular drugs, anticoagulants, and hormone therapies. They are contraindicated in individuals with pre-existing cardiovascular disease, prostate cancer, or severe hepatic or renal impairment. Specific populations, such as adolescents, women (due to virilization risks), and those with psychiatric disorders, face increased risks from AAS use.

Dosage

There is no established safe maximum dose for the non-medical use of Anabolic-Androgenic Steroids (AAS), and supraphysiological doses substantially increase the risk of adverse effects. Clinical doses for muscle wasting conditions are typically lower than those abused by athletes. For performance enhancement, an optimal dosage is not well-defined, and low-to-moderate doses in trials often do not produce significant hypertrophy in healthy adults. AAS are typically administered in cycles, with timing dependent on the specific formulation. Injectable forms generally have higher bioavailability and longer half-lives compared to oral forms. Oral 17-alpha alkylated steroids carry risks of hepatotoxicity, whereas injectable forms bypass first-pass metabolism. There are no specific cofactors required for AAS efficacy, but supportive care, such as lipid-lowering agents or liver protectants, may be considered in clinical settings to manage side effects.

FAQs

Are anabolic gaining agents safe for muscle gain?

While they can increase muscle mass and strength, Anabolic-Androgenic Steroids carry significant health risks, especially at high doses or with prolonged use, making them unsafe for general muscle gain.

Do low-to-moderate doses improve muscle hypertrophy?

Evidence suggests that low-to-moderate doses of Anabolic-Androgenic Steroids may not significantly enhance muscle hypertrophy in healthy adults, with more pronounced effects seen in clinical wasting conditions.

How quickly do effects appear?

Some muscle mass gains from Anabolic-Androgenic Steroids can be observed within weeks, but comprehensive long-term safety and efficacy data are limited.

Are adverse effects reversible?

Some adverse effects, such as lipid changes and mood alterations, may reverse after discontinuing Anabolic-Androgenic Steroids, but others, like cardiovascular damage, can be permanent.

Is monitoring required?

Yes, medical supervision is essential when using Anabolic-Androgenic Steroids to monitor cardiovascular, hepatic, and endocrine parameters due to their significant health risks.

Research Sources

https://pubmed.ncbi.nlm.nih.gov/29994823/ – This systematic review and meta-analysis of 21 RCTs found that AAS use in healthy exercising adults increased muscle strength (SMD 0.27) and lean mass (SMD 0.62). It noted that adverse effects were variably reported across studies, and limitations included short durations and doses that might not reflect real-world abuse.
https://www.scielo.br/j/ijcs/a/fqkG8rgnPX9pBSTQzvKH/?lang=en – This systematic review and meta-analysis of 6 RCTs concluded that low-to-moderate doses of AAS did not significantly improve muscle hypertrophy or lipid profiles in resistance training practitioners. It highlighted conflicting results on HDL and the need for more robust studies due to the small number of included studies and risk of bias.
https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.915159/full – This meta-analysis of 7 RCTs involving 335 COPD patients demonstrated that AAS significantly increased body weight (+1.38 kg) and fat-free mass (+1.56 kg) compared to placebo, with no significant change in fat mass. The study was limited to the COPD population, making its clinical relevance in healthy adults uncertain.
https://www.dovepress.com/the-uses-of-anabolic-androgenic-steroids-among-athletes-its-positive-a-peer-reviewed-fulltext-article-JMDH – This review discusses the uses of anabolic-androgenic steroids among athletes, covering both their positive effects on performance and the significant health risks associated with their use. It provides an overview of the motivations for use and the spectrum of adverse effects observed in athletic populations.
https://www.ncbi.nlm.nih.gov/books/NBK482418/ – This authoritative clinical overview describes the molecular mechanisms of AAS action and broad safety concerns, including significant cardiovascular and neuropsychiatric risks. As a narrative review, it synthesizes existing knowledge on the pharmacology and adverse effects of AAS, serving as a comprehensive reference for clinicians.